Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Alter the Code of Life – Technologies for Gene Editing from MammothBiosciences, San Francisco, CA

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 6/13/2019

Each CRISPR Cas protein offers different strengths in various applications because of factors like speed, precision, and cost, the company’s founders believe. Adding Cas14 to its arsenal allows Mammoth to target single-stranded DNA, as well as double-stranded DNA (Cas12) and single-stranded RNA (Cas13).

Mammoth CEO Trevor Martin thinks of DNA and RNA as the languages of CRISPR and single-stranded or double-stranded DNA and RNA as different dialects. Being able to speak multiple dialects of different languages allows Mammoth to target many different kinds of disease. The company thinks Cas14 could be particularly useful in infectious disease, oncology and genetic mutations.

https://www.fiercebiotech.com/research/new-enzyme-boosts-crispr-toolbox-for-disease-detection

https://mammoth.bio/

Mission

Mammoth’s vision is to provide a CRISPR-based platform on which an infinite number of tests can be built by both ourselves and our partners – democratizing access to an endless variety of tests for bio sensing in healthcare, as well as across industries such as agriculture, manufacturing, forensics, and more.

CRISPR Is Programmable

Both Cas12 and Cas13 are programmed by a molecule called a guide RNA. This RNA molecule matches up with the sequence we want to detect and the protein senses that a match has been found.

Reprogramming these complexes is as simple as changing the sequence of the guide RNA.

Building the CRISPR platform foundation – The Team

With expertise spanning the intersection of data analytics and molecular biology, Mammoth is building on the pioneering research conducted in Jennifer Doudna’s lab at UC Berkeley to build the CRISPR platform for the world’s best detection products.

• Jennifer Doudna
  Co-founder, Chair of Scientific
  Advisory Board
• Trevor Martin
  Co-founder, CEO
• Lucas Harrington
  Co-founder, Chief Discovery Officer

SOURCE

https://mammoth.bio/

Other 150 related articles on CRISPR published in this Open Access Online Scientific Journal include the following:

UPDATED – Gene Editing Consortium of Biotech Companies: CRISPR Therapeutics $CRSP, Intellia Therapeutics $NTLA, Caribou Biosciences, ERS Genomics, UC, Berkeley (Doudna’s IP) and University of Vienna (Charpentier’s IP), is appealing the decision ruled that there was no interference between the two sides, to the U.S. Court of Appeals for the Federal Circuit, targeting patents from The Broad Institute.

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/04/13/gene-editing-consortium-of-biotech-companies-crispr-therapeutics-crsp-intellia-therapeutics-ntla-caribou-biosciences-and-ers-genomics-uc-berkeley-doudnas-ip-and-university-of-vienna-charpe/

Top 10 CRISPR Podcasts Every Scientist (& Non-Scientist) by Synthego.com

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2019/03/09/top-10-crispr-podcasts-every-scientist-non-scientist-by-synthego-com/